SHENZHEN, Chine, 10 mai 2024 /PRNewswire/ — Le soir du 5 mai, Kexing Biopharm (code boursier : 688136) a annoncé avoir obtenu un « certificat de conformité aux BPF d’un fabricant » délivré par l’Agence norvégienne des produits médicaux conformément à la réglementation de l’Agence…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.